Aidigong Maternal & Child Health Limited Stocks

HK$ 1.31Last Updated 17.03.2025

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

HK$ 32.14M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 1.31
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aidigong Maternal & Child Health Limited, an investment holding company, provides postpartum care and healthcare services in the People's Republic of China and Hong Kong. It operates through Postpartum Care Services, Health Industry, and Other segments. The company offers maternal and child healthcare services; medical anti-aging services; healthcare industry investment services; and healthcare property development services, as well as trades in natural health food and pharmaceutical products. It also offers precision life healthcare, bio-medical technology, and management services, as well as investment and finance services. The company was formerly known as Common Splendor International Health Industry Group Limited and changed its name to Aidigong Maternal & Child Health Limited in December 2019. Aidigong Maternal & Child Health Limited is based in Kowloon Bay, Hong Kong.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks